Literature DB >> 10198301

Serum leptin concentrations and their relation to metabolic abnormalities in human sepsis.

G L Carlson1, M Saeed, R A Little, M H Irving.   

Abstract

Circulating leptin concentrations are raised in animal models of inflammation and sepsis. The purpose of this study was to determine the effect of sepsis on serum leptin concentration in humans and to examine the relationship between leptin and the metabolic consequences of sepsis. Resting energy expenditure, insulin sensitivity, and fasting serum leptin, plasma insulin, and cortisol concentrations were measured in 20 subjects with intra-abdominal sepsis and 20 healthy control subjects, before and during a 2-h period of euglycemic hyperinsulinemia. Fasting serum leptin concentrations were similar in septic and control subjects. In simple regression analysis, serum leptin concentrations correlated significantly with percent body fat in both septic patients (r = 0. 64, P < 0.005) and healthy subjects (r = 0.75, P < 0.0001). Multiple regression analyses additionally indicated that percent body fat, fasting plasma insulin, and plasma cortisol, but not sepsis, were significant and independent determinants of serum leptin concentration. No relationship between leptin and resting energy expenditure or insulin sensitivity was identifiable. A major metabolic role for leptin in human sepsis therefore appears unlikely.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10198301     DOI: 10.1152/ajpendo.1999.276.4.E658

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

Review 1.  Adipocyte, adipose tissue, and infectious disease.

Authors:  Mahalia S Desruisseaux; Maria E Trujillo; Herbert B Tanowitz; Philipp E Scherer
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  Adipokines and systemic inflammation in weight-losing lung cancer patients.

Authors:  Sule T Gulen; Fisun Karadag; Aslihan B Karul; Naciye Kilicarslan; Emel Ceylan; Nilgun K Kuman; Orhan Cildag
Journal:  Lung       Date:  2012-01-14       Impact factor: 2.584

3.  Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes.

Authors:  Marinka Kartalija; Alida R Ovrutsky; Courtney L Bryan; Gregory B Pott; Giamila Fantuzzi; Jacob Thomas; Matthew J Strand; Xiyuan Bai; Preveen Ramamoorthy; Micol S Rothman; Vijaya Nagabhushanam; Michael McDermott; Adrah R Levin; Ashley Frazer-Abel; Patricia C Giclas; Judith Korner; Michael D Iseman; Leland Shapiro; Edward D Chan
Journal:  Am J Respir Crit Care Med       Date:  2012-11-09       Impact factor: 21.405

4.  Correlation of crevicular fluid and serum levels of retinol-binding protein 4 and leptin in chronic periodontitis and obesity.

Authors:  Dharmendra Kanoriya; A R Pradeep; A Mallika; Sandeep Singhal; Vibhuti Garg
Journal:  Clin Oral Investig       Date:  2016-12-08       Impact factor: 3.573

5.  Leptin in sepsis: a well-suited biomarker in critically ill patients?

Authors:  Rodolfo Leonel Bracho-Riquelme; Miguel Arturo Reyes-Romero
Journal:  Crit Care       Date:  2010-04-09       Impact factor: 9.097

6.  Leptin in septic arthritis: decreased levels during infection and amelioration of disease activity upon its administration.

Authors:  O H Hultgren; A Tarkowski
Journal:  Arthritis Res       Date:  2001-09-19

Review 7.  Impact of Obesity on the Course of Management of Inflammatory Bowel Disease-A Review.

Authors:  Agata Michalak; Beata Kasztelan-Szczerbińska; Halina Cichoż-Lach
Journal:  Nutrients       Date:  2022-09-25       Impact factor: 6.706

8.  Adiponectin, retinol-binding protein 4, and leptin in protracted critical illness of pulmonary origin.

Authors:  Lies Langouche; Sarah Vander Perre; Jan Frystyk; Allan Flyvbjerg; Troels Krarup Hansen; Greet Van den Berghe
Journal:  Crit Care       Date:  2009-07-09       Impact factor: 9.097

9.  Effects of TNF-alpha and leptin on weight loss in patients with stable chronic obstructive pulmonary disease.

Authors:  Kyeong-Cheol Shin; Jin Hong Chung; Kwan Ho Lee
Journal:  Korean J Intern Med       Date:  2007-12       Impact factor: 3.165

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.